Implementing CYP2C19 Pharmacogenetic Testing for Personalized Antiplatelet Therapy: Findings From the QPGx-CARES Initiative
<h3 dir="ltr">Purpose</h3><p dir="ltr">CYP2C19 loss-of-function (LoF) alleles are associated with increased cardiovascular risk in clopidogrel-treated percutaneous coronary intervention (PCI) patients. Despite the guidelines recommendation for newer P2Y12 inhibi...
محفوظ في:
| المؤلف الرئيسي: | |
|---|---|
| مؤلفون آخرون: | , , , , , , , , , |
| منشور في: |
2025
|
| الموضوعات: | |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|
| _version_ | 1864513508246290432 |
|---|---|
| author | Rania Abdel-latif (18295396) |
| author2 | Wadha Al Muftah (3466304) Shaban Mohammed (14150130) Toka AlHsson (22963138) Daoud Al-Badriyeh (832403) Radja Badji (14152548) Awad Al-Qahtani (315456) Abdul Rahman Arabi (12506942) Said Ismail (1567891) Moza Al Hail (2511859) Jassim Al Suwaidi (284932) |
| author2_role | author author author author author author author author author author |
| author_facet | Rania Abdel-latif (18295396) Wadha Al Muftah (3466304) Shaban Mohammed (14150130) Toka AlHsson (22963138) Daoud Al-Badriyeh (832403) Radja Badji (14152548) Awad Al-Qahtani (315456) Abdul Rahman Arabi (12506942) Said Ismail (1567891) Moza Al Hail (2511859) Jassim Al Suwaidi (284932) |
| author_role | author |
| dc.creator.none.fl_str_mv | Rania Abdel-latif (18295396) Wadha Al Muftah (3466304) Shaban Mohammed (14150130) Toka AlHsson (22963138) Daoud Al-Badriyeh (832403) Radja Badji (14152548) Awad Al-Qahtani (315456) Abdul Rahman Arabi (12506942) Said Ismail (1567891) Moza Al Hail (2511859) Jassim Al Suwaidi (284932) |
| dc.date.none.fl_str_mv | 2025-12-26T09:00:00Z |
| dc.identifier.none.fl_str_mv | 10.1016/j.clinthera.2025.12.003 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/journal_contribution/Implementing_CYP2C19_Pharmacogenetic_Testing_for_Personalized_Antiplatelet_Therapy_Findings_From_the_QPGx-CARES_Initiative/31017433 |
| dc.rights.none.fl_str_mv | CC BY 4.0 info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Biomedical and clinical sciences Cardiovascular medicine and haematology Pharmacology and pharmaceutical sciences Antiplatelet therapy Cardiology CYP2C19 Pharmacogenetics Point-of-Care |
| dc.title.none.fl_str_mv | Implementing CYP2C19 Pharmacogenetic Testing for Personalized Antiplatelet Therapy: Findings From the QPGx-CARES Initiative |
| dc.type.none.fl_str_mv | Text Journal contribution info:eu-repo/semantics/publishedVersion text contribution to journal |
| description | <h3 dir="ltr">Purpose</h3><p dir="ltr">CYP2C19 loss-of-function (LoF) alleles are associated with increased cardiovascular risk in clopidogrel-treated percutaneous coronary intervention (PCI) patients. Despite the guidelines recommendation for newer P2Y12 inhibitors, clopidogrel remains widely prescribed. The study the potential impact and feasibility of implementing pharmacogenetics (PGx) testing to guide antiplatelet therapy and develop strategies for its clinical integration to improve patient management. </p><h3 dir="ltr">Methods</h3><p dir="ltr">A pilot study following a prospective cohort design was conducted within the largest community healthcare provider in Qatar using point-of-care (POC) CYP2C19 genotyping in tailoring antiplatelet therapy for PCI patients. Eligible patients underwent CYP2C19 genotyping, and P2Y12 inhibitor prescriptions were adjusted based on genetic results. The study measured antiplatelet prescribing patterns and identified clinically significant gene-drug interactions. </p><h3 dir="ltr">Findings</h3><p dir="ltr">Out of 376 patients tested, 283 patients received PGx-guided recommendations for anti-platelet therapy. Actionable CYP2C19 alleles were detected in 22% of those patients, prompting a change in drug therapy. PGx-guided recommendations were adopted at a rate of 80%, and CYP2C19 genotyping was a significant predictor of antiplatelet therapy adjustments. A sub-analysis of the cost impact revealed an estimated reduction of 300 QR (82.41 $) per patient annually for ACS patients who underwent PCI with stent placement. </p><h3 dir="ltr">Implications</h3><p dir="ltr">This real-world study highlights the feasibility and clinical impact of CYP2C19 genotyping in guiding antiplatelet therapy for ACS and PCI patients, supporting broader PGx testing implementation in routine cardiovascular care. </p><h3 dir="ltr">Trail registration</h3><p dir="ltr">HMC-IRB Registration: IRB-HMC-2021-011, IRB-MoPH Assurance: IRB-A-HMC-2019-0014. ISRCTN registration: ISRCTN15110009, https://www.isrctn.com/ISRCTN15110009.</p><h2 dir="ltr">Other Information</h2><p dir="ltr">Published in: Clinical Therapeutics<br>License: <a href="http://creativecommons.org/licenses/by/4.0/" target="_blank">http://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1016/j.clinthera.2025.12.003" target="_blank">https://dx.doi.org/10.1016/j.clinthera.2025.12.003</a></p> |
| eu_rights_str_mv | openAccess |
| id | Manara2_a4c2d42229aa05693b2c656e3f1f5dc2 |
| identifier_str_mv | 10.1016/j.clinthera.2025.12.003 |
| network_acronym_str | Manara2 |
| network_name_str | Manara2 |
| oai_identifier_str | oai:figshare.com:article/31017433 |
| publishDate | 2025 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY 4.0 |
| spelling | Implementing CYP2C19 Pharmacogenetic Testing for Personalized Antiplatelet Therapy: Findings From the QPGx-CARES InitiativeRania Abdel-latif (18295396)Wadha Al Muftah (3466304)Shaban Mohammed (14150130)Toka AlHsson (22963138)Daoud Al-Badriyeh (832403)Radja Badji (14152548)Awad Al-Qahtani (315456)Abdul Rahman Arabi (12506942)Said Ismail (1567891)Moza Al Hail (2511859)Jassim Al Suwaidi (284932)Biomedical and clinical sciencesCardiovascular medicine and haematologyPharmacology and pharmaceutical sciencesAntiplatelet therapyCardiologyCYP2C19PharmacogeneticsPoint-of-Care<h3 dir="ltr">Purpose</h3><p dir="ltr">CYP2C19 loss-of-function (LoF) alleles are associated with increased cardiovascular risk in clopidogrel-treated percutaneous coronary intervention (PCI) patients. Despite the guidelines recommendation for newer P2Y12 inhibitors, clopidogrel remains widely prescribed. The study the potential impact and feasibility of implementing pharmacogenetics (PGx) testing to guide antiplatelet therapy and develop strategies for its clinical integration to improve patient management. </p><h3 dir="ltr">Methods</h3><p dir="ltr">A pilot study following a prospective cohort design was conducted within the largest community healthcare provider in Qatar using point-of-care (POC) CYP2C19 genotyping in tailoring antiplatelet therapy for PCI patients. Eligible patients underwent CYP2C19 genotyping, and P2Y12 inhibitor prescriptions were adjusted based on genetic results. The study measured antiplatelet prescribing patterns and identified clinically significant gene-drug interactions. </p><h3 dir="ltr">Findings</h3><p dir="ltr">Out of 376 patients tested, 283 patients received PGx-guided recommendations for anti-platelet therapy. Actionable CYP2C19 alleles were detected in 22% of those patients, prompting a change in drug therapy. PGx-guided recommendations were adopted at a rate of 80%, and CYP2C19 genotyping was a significant predictor of antiplatelet therapy adjustments. A sub-analysis of the cost impact revealed an estimated reduction of 300 QR (82.41 $) per patient annually for ACS patients who underwent PCI with stent placement. </p><h3 dir="ltr">Implications</h3><p dir="ltr">This real-world study highlights the feasibility and clinical impact of CYP2C19 genotyping in guiding antiplatelet therapy for ACS and PCI patients, supporting broader PGx testing implementation in routine cardiovascular care. </p><h3 dir="ltr">Trail registration</h3><p dir="ltr">HMC-IRB Registration: IRB-HMC-2021-011, IRB-MoPH Assurance: IRB-A-HMC-2019-0014. ISRCTN registration: ISRCTN15110009, https://www.isrctn.com/ISRCTN15110009.</p><h2 dir="ltr">Other Information</h2><p dir="ltr">Published in: Clinical Therapeutics<br>License: <a href="http://creativecommons.org/licenses/by/4.0/" target="_blank">http://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1016/j.clinthera.2025.12.003" target="_blank">https://dx.doi.org/10.1016/j.clinthera.2025.12.003</a></p>2025-12-26T09:00:00ZTextJournal contributioninfo:eu-repo/semantics/publishedVersiontextcontribution to journal10.1016/j.clinthera.2025.12.003https://figshare.com/articles/journal_contribution/Implementing_CYP2C19_Pharmacogenetic_Testing_for_Personalized_Antiplatelet_Therapy_Findings_From_the_QPGx-CARES_Initiative/31017433CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/310174332025-12-26T09:00:00Z |
| spellingShingle | Implementing CYP2C19 Pharmacogenetic Testing for Personalized Antiplatelet Therapy: Findings From the QPGx-CARES Initiative Rania Abdel-latif (18295396) Biomedical and clinical sciences Cardiovascular medicine and haematology Pharmacology and pharmaceutical sciences Antiplatelet therapy Cardiology CYP2C19 Pharmacogenetics Point-of-Care |
| status_str | publishedVersion |
| title | Implementing CYP2C19 Pharmacogenetic Testing for Personalized Antiplatelet Therapy: Findings From the QPGx-CARES Initiative |
| title_full | Implementing CYP2C19 Pharmacogenetic Testing for Personalized Antiplatelet Therapy: Findings From the QPGx-CARES Initiative |
| title_fullStr | Implementing CYP2C19 Pharmacogenetic Testing for Personalized Antiplatelet Therapy: Findings From the QPGx-CARES Initiative |
| title_full_unstemmed | Implementing CYP2C19 Pharmacogenetic Testing for Personalized Antiplatelet Therapy: Findings From the QPGx-CARES Initiative |
| title_short | Implementing CYP2C19 Pharmacogenetic Testing for Personalized Antiplatelet Therapy: Findings From the QPGx-CARES Initiative |
| title_sort | Implementing CYP2C19 Pharmacogenetic Testing for Personalized Antiplatelet Therapy: Findings From the QPGx-CARES Initiative |
| topic | Biomedical and clinical sciences Cardiovascular medicine and haematology Pharmacology and pharmaceutical sciences Antiplatelet therapy Cardiology CYP2C19 Pharmacogenetics Point-of-Care |